Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Symbol: 002603.SZ

SHZ

19.58

CNY

Market price today

  • 12.0881

    P/E Ratio

  • 0.2763

    PEG Ratio

  • 32.71B

    MRK Cap

  • 0.03%

    DIV Yield

Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603-SZ) Financial Statements

On the chart you can see the default numbers in dynamics for Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ). Companys revenue shows the average of 4426.104 M which is 0.201 % gowth. The average gross profit for the whole period is 2862.493 M which is 0.203 %. The average gross profit ratio is 0.649 %. The net income growth for the company last year performance is 0.757 % which equals 0.291 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Shijiazhuang Yiling Pharmaceutical Co., Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.266. In the realm of current assets, 002603.SZ clocks in at 7254.187 in the reporting currency. A significant portion of these assets, precisely 2422.66, is held in cash and short-term investments. This segment shows a change of 1.306% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 830.52, if any, in the reporting currency. This indicates a difference of -1630.261% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 215.123 in the reporting currency. This figure signifies a year_over_year change of -0.151%. Shareholder value, as depicted by the total shareholder equity, is valued at 10932.217 in the reporting currency. The year over year change in this aspect is 0.205%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 2699.567, with an inventory valuation of 2021.82, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 827.96.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014201320122011201020092008

balance-sheet.row.cash-and-short-term-investments

5918.122422.71050.51554
1026.1
1129
802.7
534.1
430.6
401.5
709.6
1499.1
1962.5
403.1
210.8
126.1

balance-sheet.row.short-term-investments

960.06518.455.3217
292.7
351.8
-26.4
-304.5
-28.7
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

11401.272699.62593.12102.4
2765.8
2207.2
1379.2
938.8
784.9
589.1
882.9
739.8
924
280.8
765.7
329.9

balance-sheet.row.inventory

9398.482021.81672.71580.3
1221.8
1175.7
1075.6
921.7
1037.9
833.7
618.4
455.7
326.7
210.1
144.4
67.8

balance-sheet.row.other-current-assets

764.15110.1285.8222.7
54.5
386.3
889.1
131.6
69
418.1
484.4
0
-30.6
-1.2
-192.1
-78.2

balance-sheet.row.total-current-assets

27482.027254.25602.15459.4
5068.2
4898.3
4146.6
2526.2
2322.3
2242.4
2695.3
2694.5
3182.6
892.8
928.8
445.7

balance-sheet.row.property-plant-equipment-net

28847.516221.85745.54299.1
3051.2
2852.6
2997.6
2727.2
2729
1963.1
1526.8
1105.3
764.4
622.9
485.8
350.9

balance-sheet.row.goodwill

458.41000
0
0
11.9
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

1788.73828897.9736.6
754.4
562
537.8
514.6
466.6
378.5
354
340.7
263.8
246.8
90.6
32.1

balance-sheet.row.goodwill-and-intangible-assets

2247.15828897.9736.6
754.4
562
549.7
514.6
466.6
378.5
354
340.7
263.8
246.8
90.6
32.1

balance-sheet.row.long-term-investments

6697.79830.5-54.3-216
-291.7
-301.3
117
373.5
31.3
44.1
0
0
0
0
0
0

balance-sheet.row.tax-assets

644.07279.9117137.8
68.1
59.2
35.4
29.8
33.9
27.9
15.8
20.8
10.5
7.3
3.4
2.4

balance-sheet.row.other-non-current-assets

3777.87921.8596.61075.3
419.3
486.4
41.1
79.2
123.9
431.8
66.1
4.4
4.1
1.3
0.8
0.9

balance-sheet.row.total-non-current-assets

42214.389081.97302.76032.9
4001.2
3659
3740.8
3724.2
3384.6
2845.5
1962.7
1471.2
1042.8
878.3
580.6
386.2

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

69696.416336.112904.811492.3
9069.4
8557.2
7887.4
6250.5
5707
5087.9
4658
4165.7
4225.4
1771.1
1509.4
831.9

balance-sheet.row.account-payables

9244.982060.81621.21188.4
506.8
389
353
307.7
373.2
247.1
141.9
69.8
72.8
86.5
115.9
46.4

balance-sheet.row.short-term-debt

5000.64656.3513.9270.2
50.1
0
0
100
50
0
0
0
201
160
0
30

balance-sheet.row.tax-payables

514.42474123.2133.9
99.5
94.9
89.8
106.1
40.2
24.1
-1.3
1.7
37.4
143
110.8
2.8

balance-sheet.row.long-term-debt-total

2224.33215.151310.5
0
0
0
0
0
0
0
47
47
46
0
0

Deferred Revenue Non Current

1093.93335357.8328.1
310.4
228.9
168.3
177.2
172.1
166.5
159.8
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

511.13---
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

969.931027.3216.328.3
46.2
375.6
254.2
99.3
60.8
120.2
105.1
60.4
28.8
45.3
524.9
19.9

balance-sheet.row.total-non-current-liabilities

3857.23555.7872.2330.1
310.4
228.9
168.3
177.2
172.1
166.5
152.7
190.5
149.8
146
78.1
59.5

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

53.781512.510.5
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

22620.855405.83832.72569
1116.9
993.6
775.6
917.8
879.6
533.8
399.7
320.8
523.8
680.1
718.9
347.9

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

6682.821670.71670.71203.7
1203.7
1206.3
1204.6
1128.8
1127.6
563.4
563.9
552.5
425
360
79.9
79.9

balance-sheet.row.retained-earnings

26988.465989.24306.24324.4
3483.1
3071.7
2650.1
2290
1902.1
1562.9
1293.1
1117.9
990.9
571.9
564.6
267.5

balance-sheet.row.accumulated-other-comprehensive-income-loss

8525.75989808.9640.9
507.3
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

4566.632283.32283.32750.3
2750.3
3283.1
3255.5
1903
1785.9
2427.8
2401.4
2174.6
2285.8
159.1
143.3
134.2

balance-sheet.row.total-stockholders-equity

46763.6610932.29069.18919.3
7944.4
7561.1
7110.2
5321.8
4815.6
4554.1
4258.3
3845
3701.6
1091
787.7
481.5

balance-sheet.row.total-liabilities-and-stockholders-equity

69696.416336.112904.811492.3
9069.4
8557.2
7887.4
6250.5
5707
5087.9
4658
4165.7
4225.4
1771.1
1509.4
831.9

balance-sheet.row.minority-interest

-40.48-1.934.1
8.1
2.5
1.6
10.8
11.8
0
0
0
0
0
2.9
2.5

balance-sheet.row.total-equity

46723.1810930.39072.28923.4
7952.5
7563.7
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

69696.4---
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

7657.841348.911
1
50.5
90.6
69
2.5
44.1
0
0
0
0
0
0

balance-sheet.row.total-debt

7252.82871.41026.9270.2
50.1
0
0
100
50
0
0
47
248
206
0
30

balance-sheet.row.net-debt

2294.75-1032.831.6-1066.8
-683.4
-777.3
-802.7
-434.1
-380.6
-401.5
-709.6
-1452.1
-1714.5
-197.1
-210.8
-96.1

Cash Flow Statement

The financial landscape of Shijiazhuang Yiling Pharmaceutical Co., Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 23.599. The company recently extended its share capital by issuing 0, marking a difference of 0.000 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 1886.22 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -1994800827.610 in the reporting currency. This is a shift of 2.936 from the previous year. In the same period, the company recorded 451.47, 0, and -2200.01, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -282.7 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 1845.71, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014201320122011201020092008

cash-flows.row.net-income

453.792356.81341.61214.9
603
593
536.8
535.9
426.8
354.5
244.3
185.8
454.1
315
297.5
122.3

cash-flows.row.depreciation-and-amortization

18.64451.5362.9268.2
259.7
253.2
244.7
216.8
144.6
85.5
64
61.2
58.7
49
34.1
29.7

cash-flows.row.deferred-income-tax

0-158.720.1-67.7
-8.9
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0158.7-20.167.7
8.9
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

0547.8-1309.724.8
-856.5
-760.4
-659.7
-138
-443.1
-341.5
-264.6
-189.9
-941
-61.1
-20.6
53.8

cash-flows.row.account-receivables

0-831.7-1280.3-668.7
-800.4
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0-348-104.7-364.9
-40.8
-105.4
-148
116.1
-204.1
-212.6
-162.7
-128.9
-116.6
-65.7
-76.6
7.1

cash-flows.row.account-payables

01886.255.11126.1
-6.4
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0-158.720.1-67.7
-8.9
-655
-511.7
-254.2
-239
-128.8
-101.9
-61
-824.4
4.6
56.1
46.6

cash-flows.row.other-non-cash-items

-279.24131.6133.978.3
62.7
-13.4
-7.1
16.9
3.6
7.3
11.6
13.1
19.7
-3.2
7.2
4.4

cash-flows.row.net-cash-provided-by-operating-activities

-97.94000
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-266.96-214-673.6-1144.8
-454.4
-187.2
-180.3
-373
-478.4
-450.2
-409.8
-296.9
-177.9
-285
-210.6
-128.3

cash-flows.row.acquisitions-net

-675.790.42.41145.1
7.1
0
-1.7
373.2
478.5
450.6
409.9
0
0
-25.6
0
0

cash-flows.row.purchases-of-investments

-2677.83-3461.9-451-2853.3
-2114.8
-1374.8
-1756.5
-247.1
-89.3
-1500.8
-1210
0
0
287.8
0
0

cash-flows.row.sales-maturities-of-investments

4232.641680.7616.62957.6
2599
1599.7
985
115.1
462.6
1596.9
733.9
0
0
0.6
0
0

cash-flows.row.other-investing-activites

0.360-1.2-1144.8
0.2
8.6
1.1
-373
-478.4
-450.2
-409.8
0.2
0
-285
0
0.2

cash-flows.row.net-cash-used-for-investing-activites

612.43-1994.8-506.8-1040.2
37.1
46.4
-952.5
-504.9
-105
-353.7
-885.9
-296.7
-177.9
-307.2
-210.6
-128.1

cash-flows.row.debt-repayment

-651.63-2200-1469.9-270
-50
0
-100
-50
-60
0
-47
-251
-261
0
-110
-30

cash-flows.row.common-stock-issued

0000
50
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
-100
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

-1236.19-282.7-1220.1-244.1
-119.8
-120.6
-103.1
-86.9
-58.4
-55.2
-56.1
-35.9
-56.1
-4.8
-1.9
-83.7

cash-flows.row.other-financing-activites

1548.011845.72387.9490.8
50.2
-23.2
1295.8
113.5
120.8
-5.1
144.2
50
2462.8
204.5
89
94.5

cash-flows.row.net-cash-used-provided-by-financing-activities

-344.34-637-302.1-23.3
-169.6
-143.9
1092.7
-23.3
2.4
-60.3
41.2
-236.9
2145.7
199.7
-22.9
-19.2

cash-flows.row.effect-of-forex-changes-on-cash

0.61.2-0.5-2
-0.6
0
-0.2
0.1
-0.2
0.1
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

168.43857.2-280.7520.8
-64.2
-25.1
254.6
103.5
29.1
-308.1
-789.4
-463.4
1559.4
192.3
84.7
62.9

cash-flows.row.cash-at-end-of-period

4775.11810.7953.51234.2
713.4
777.6
802.7
534.1
430.6
401.5
709.6
1499.1
1962.5
403.1
210.8
126.1

cash-flows.row.cash-at-beginning-of-period

4606.67953.51234.2713.4
777.6
802.7
548.1
430.6
401.5
709.6
1499.1
1962.5
403.1
210.8
126.1
63.3

cash-flows.row.operating-cash-flow

-97.943487.7528.71586.2
68.9
72.4
114.7
631.6
131.9
105.9
55.3
70.1
-408.5
299.7
318.2
210.2

cash-flows.row.capital-expenditure

-266.96-214-673.6-1144.8
-454.4
-187.2
-180.3
-373
-478.4
-450.2
-409.8
-296.9
-177.9
-285
-210.6
-128.3

cash-flows.row.free-cash-flow

-364.93273.8-144.9441.4
-385.5
-114.9
-65.7
258.6
-346.6
-344.3
-354.5
-226.8
-586.4
14.7
107.6
81.9

Income Statement Row

Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s revenue saw a change of 0.239% compared with the previous period. The gross profit of 002603.SZ is reported to be 7992.27. The company's operating expenses are 5025.83, showing a change of 5.614% from the last year. The expenses for depreciation and amortization are 451.47, which is a 0.217% change from the last accounting period. Operating expenses are reported to be 5025.83, which shows a 5.614% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.803% year-over-year growth. The operating income is 2829.56, which shows a 0.803% change when compared to the previous year. The change in the net income is 0.757%. The net income for the last year was 2361.8.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014201320122011201020092008

income-statement-row.row.total-revenue

8836.7612532.810116.88782.5
5825.3
4814.6
4081.3
3820.2
3184.8
2921.2
2490.2
1648.7
1953.2
1649.3
1632.3
938.6

income-statement-row.row.cost-of-revenue

4301.714540.636813118.4
2106.2
1630.8
1303.9
1287.7
1164.4
1077.7
830.5
524
617.7
554.7
636.8
379.7

income-statement-row.row.gross-profit

4535.057992.36435.85664.1
3719.1
3183.7
2777.4
2532.5
2020.3
1843.5
1659.7
1124.6
1335.5
1094.6
995.5
558.8

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

860.36---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

262.88---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

1358.25---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-42.42576.9366.6323
301.6
-17.9
-10.9
14.3
0.7
3.9
16.1
28.1
42.9
23.8
15.7
-6

income-statement-row.row.operating-expenses

3928.535025.84758.74179.2
3034
2499.5
2144.1
1904
1541.9
1462.3
1424.8
975.5
846.7
747.5
650.5
404.6

income-statement-row.row.cost-and-expenses

8230.249566.48439.77297.6
5140.2
4130.3
3448.1
3191.7
2706.3
2540
2255.3
1499.5
1464.4
1302.2
1287.4
784.3

income-statement-row.row.interest-income

22.912.920.47
2.3
17.7
4.7
-1.9
2.8
8.6
34.3
50.6
26.6
1.8
1.1
0.5

income-statement-row.row.interest-expense

42.4133.8343.8
0.1
0
1.5
3.2
2.8
2.8
0
6.9
20.2
7.9
2
1.7

income-statement-row.row.selling-and-marketing-expenses

1358.25---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-24.14-48.9-15.4-15.6
-2.3
16.8
5.1
9.2
20.9
29.4
54.5
67.1
43.7
21.6
9.3
-10

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-42.42576.9366.6323
301.6
-17.9
-10.9
14.3
0.7
3.9
16.1
28.1
42.9
23.8
15.7
-6

income-statement-row.row.total-operating-expenses

-24.14-48.9-15.4-15.6
-2.3
16.8
5.1
9.2
20.9
29.4
54.5
67.1
43.7
21.6
9.3
-10

income-statement-row.row.interest-expense

42.4133.8343.8
0.1
0
1.5
3.2
2.8
2.8
0
6.9
20.2
7.9
2
1.7

income-statement-row.row.depreciation-and-amortization

124.37546.1448.6329.5
261.4
253.2
244.7
216.8
144.6
85.5
64
61.2
58.7
49
34.1
29.7

income-statement-row.row.ebitda-caps

747---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

620.632829.61569.11438
710.2
719
649.2
623.7
499
410
273.2
188.2
489.6
345.7
339.6
150.4

income-statement-row.row.income-before-tax

596.492780.61553.71422.5
707.9
701
638.3
637.7
499.4
410.6
289.3
216.2
532.5
368.8
354.3
144.2

income-statement-row.row.income-tax-expense

151.7423.8212.1207.5
104.8
108
101.6
101.8
72.6
56.1
45
30.4
78.4
53.7
56.8
22

income-statement-row.row.net-income

453.792361.81343.91218.7
606.5
599.2
540.7
542
430.5
354.5
244.3
185.8
454.1
315.6
297.2
122.1

Frequently Asked Question

What is Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) total assets?

Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) total assets is 16336112689.000.

What is enterprise annual revenue?

The annual revenue is 4197033558.000.

What is firm profit margin?

Firm profit margin is 0.630.

What is company free cash flow?

The free cash flow is 0.986.

What is enterprise net profit margin?

The net profit margin is 0.206.

What is firm total revenue?

The total revenue is 0.243.

What is Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) net profit (net income)?

The net profit (net income) is 2361804714.000.

What is firm total debt?

The total debt is 871449540.000.

What is operating expences number?

The operating expences are 5025828583.000.

What is company cash figure?

Enretprise cash is 1189759394.000.